Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ZTS 
Zoetis Inc (ZTS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: ZTS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
19 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $188.83
1 Year Target Price $188.83
| 10 | Strong Buy |
| 4 | Buy |
| 5 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -14.17% | Avg. Invested days 49 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 63.58B USD | Price to earnings Ratio 24.52 | 1Y Target Price 188.83 |
Price to earnings Ratio 24.52 | 1Y Target Price 188.83 | ||
Volume (30-day avg) 19 | Beta 0.9 | 52 Weeks Range 138.76 - 194.18 | Updated Date 10/14/2025 |
52 Weeks Range 138.76 - 194.18 | Updated Date 10/14/2025 | ||
Dividends yield (FY) 1.31% | Basic EPS (TTM) 5.85 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 27.83% | Operating Margin (TTM) 40.65% |
Management Effectiveness
Return on Assets (TTM) 15.44% | Return on Equity (TTM) 52.77% |
Valuation
Trailing PE 24.52 | Forward PE 21.69 | Enterprise Value 70277946813 | Price to Sales(TTM) 6.77 |
Enterprise Value 70277946813 | Price to Sales(TTM) 6.77 | ||
Enterprise Value to Revenue 7.49 | Enterprise Value to EBITDA 17.49 | Shares Outstanding 443183472 | Shares Floating 442310401 |
Shares Outstanding 443183472 | Shares Floating 442310401 | ||
Percent Insiders 0.09 | Percent Institutions 98.68 |
Upturn AI SWOT
Zoetis Inc
Company Overview
History and Background
Zoetis Inc. was founded in 2013, spun off from Pfizer's animal health division. It quickly became a global leader in animal health, focusing on discovering, developing, manufacturing, and commercializing veterinary vaccines, medicines, diagnostics, and genetic tests.
Core Business Areas
- Livestock: Develops and markets a diverse portfolio of products for livestock, including cattle, swine, poultry, and fish. These products include vaccines, parasiticides, and other pharmaceuticals.
- Companion Animal: Offers a range of products for companion animals like dogs, cats, and horses. Key products include vaccines, parasiticides, pain management medications, and dermatology products.
- Diagnostics: Provides diagnostic products and services used by veterinarians to detect and monitor animal diseases.
Leadership and Structure
Zoetis is led by Kristin Peck (CEO). The organizational structure includes various business units and functions, such as R&D, manufacturing, commercial operations, and finance. There is also a board of directors that oversees the company's strategy and performance.
Top Products and Market Share
Key Offerings
- Market Share: Estimated market share in the US of Simparica Trio is approximately 15%.
- Product Name 1: Simparica Trio: A monthly chewable tablet for dogs that protects against heartworm disease, fleas, ticks, roundworms, and hookworms. It holds a significant market share in the parasiticides market for companion animals. Competitors include NexGard and Bravecto.
- Market Share: Estimated market share in the US of Draxxin is approximately 20% in the BRD treatment segment.
- Product Name 2: Draxxin: An injectable antibiotic used to treat bovine respiratory disease (BRD) and swine respiratory disease (SRD). It has a large market share in the livestock antibiotic market. Competitors are generic antibiotics and other branded antibiotic solutions.
Market Dynamics
Industry Overview
The animal health industry is experiencing growth driven by factors such as increasing pet ownership, rising demand for animal protein, and growing awareness of animal health issues. The industry is characterized by innovation in pharmaceuticals, vaccines, and diagnostics.
Positioning
Zoetis is a leading player in the animal health industry, with a strong global presence and a broad portfolio of products and services. Its competitive advantages include its R&D capabilities, strong brand recognition, and established distribution network.
Total Addressable Market (TAM)
The global animal health market is estimated to be around $50 billion annually. Zoetis is well-positioned to capture a significant share of this market due to its diversified product portfolio and global reach.
Upturn SWOT Analysis
Strengths
- Strong brand recognition
- Broad product portfolio
- Global distribution network
- Robust R&D pipeline
- Experienced management team
Weaknesses
- Dependence on regulatory approvals
- Exposure to generic competition
- Vulnerability to economic downturns
- Risk of product liability claims
Opportunities
- Expanding into emerging markets
- Developing innovative products and services
- Acquiring complementary businesses
- Leveraging digital technologies
- Focusing on preventative healthcare for animals
Threats
- Increasing competition
- Changing regulations
- Economic slowdown
- Disease outbreaks
- Supply chain disruptions
Competitors and Market Share
Key Competitors
- ELAN
- MRK
- LLY
Competitive Landscape
Zoetis benefits from scale and product breadth. ELAN and MRK compete primarily within specific market segments such as livestock or companion animal.
Major Acquisitions
Jinyu Bio
- Year: 2019
- Acquisition Price (USD millions): 137
- Strategic Rationale: Expanded Zoetisu2019s presence in the Chinese livestock vaccine market.
Abaxis
- Year: 2018
- Acquisition Price (USD millions): 2000
- Strategic Rationale: Expanded Zoetisu2019s presence in the veterinary diagnostics space.
Growth Trajectory and Initiatives
Historical Growth: Zoetis has experienced consistent revenue and earnings growth over the past several years, driven by organic growth and strategic acquisitions.
Future Projections: Analysts project continued growth for Zoetis, driven by increasing demand for animal health products and services. Revenue is projected to grow at a rate of 7-9% annually over the next five years.
Recent Initiatives: Recent strategic initiatives include the acquisition of Jinyu Bio and the expansion of its R&D pipeline.
Summary
Zoetis is a strong company with a dominant position in the growing animal health market. Their diverse portfolio and global reach are working well, driving revenue growth and shareholder returns. However, they should be mindful of increasing competition and regulatory changes in the industry and maintain a focus on R&D.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company reports
- Analyst estimates
- Industry publications
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on individual circumstances and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Zoetis Inc
Exchange NYSE | Headquaters Parsippany, NJ, United States | ||
IPO Launch date 2013-02-01 | CEO & Director Ms. Kristin C. Peck | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 13800 | Website https://www.zoetis.com |
Full time employees 13800 | Website https://www.zoetis.com | ||
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1950 and is headquartered in Parsippany, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.